Adverum is a clinical-stage gene therapy company targeting unmet medical need in ocular and rare diseases. We develop gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Our core capabilities include clinical development, novel vector discovery, and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices (cGMP) quality control. Our team has extensive clinical development experience and is laser-focused on advancing novel gene therapies for patients. Source
No articles found.
CollPlant is a regenerative medicine company focused on 3D bioprinting of tissues ...
CollPlant is a regenerative medicine company fo...
Systec & Solutions GmbH, with headquarters in Karlsruhe (Germany), is a specialize...
Systec & Solutions GmbH, with headquarters in K...
Akcea Therapeutics is a development and commercialization company focused on helpi...
Akcea Therapeutics is a development and commerc...
Axogen (AXGN) is a global leader in innovative surgical solutions for peripheral n...
Axogen (AXGN) is a global leader in innovative ...
IDEXX Laboratories, Inc. is a member of the S&P 500ÂŽ Index and is a leader in pet...
IDEXX Laboratories, Inc. is a member of the S&P...
Cool your patients to a target temperature of 33ÂşC in about 30 minutes with Life ...
Cool your patients to a target temperature of 3...
Tocagen is a clinical-stage, cancer-selective gene therapy company developing firs...
Tocagen is a clinical-stage, cancer-selective g...
Join the National Investor Network and get the latest information with your interests in mind.